Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients

Table 2 Adjusted logistic regression for factors associated with virological treatment failure

Covariables	Model 1		Model 2		Model 3		Model 4
	OR (95%CI)	P value	OR (95% CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
	n = 538		n = 538		n = 526		n = 395
Age at treatment initiation (per 10 yr)	1.2 (0.6-2.4)	0.58	1.3 (0.7-2.5)	0.48	1.2 (0.6-2.4)	0.53	1.6 (0.7-4.0)	0.29
Ribavirin vs no ribavirin	1.0 (0.3-3.0)	0.97	1.1 (0.3-3.2)	0.93	1.0 (0.3-3.0)	0.97	1.4 (0.4-5.5)	0.61
Male sex vs female	1.0 (0.4-2.8)	0.98	0.9 (0.3-2.7)	0.92	1.0 (0.3-2.8)	0.97	0.8 (0.2-2.7)	0.69
Treatment duration 24 wk vs 12 wk	0.4 (0.1-1.4)	0.15	0.5 (0.2-1.5)	0.21	0.4 (0.1-1.4)	0.16	0.2 (0.0-1.0)	0.05
Platelet count < 100 Giga/L vs ≥ 100							6.5 (1.8-22.6)	0.004
Cirrhosis vs no cirrhosis	1.4 (0.5-3.9)	0.51
HIV-RNA detectable vs undetectable			2.1 (0.7-5.9)	0.17
Severe cirrhosis vs no severe cirrhosis					2.1 (0.4-10.3)	0.35
HCV genotype 3 vs others							0.9 (0.1-7.5)	0.91

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.